de Boo, L W; Jóźwiak, K; Ter Hoeve, N D; van Diest, P J; Opdam, M; Wang, Y; Schmidt, M K; de Jong, V; Kleiterp, S; Cornelissen, S; Baars, D; Koornstra, R H T; Kerver, E D; van Dalen, T; Bins, A D; Beeker, A; van den Heiligenberg, S M; de Jong, P C; Bakker, S D; Rietbroek, R C; Konings, I R; Blankenburgh, R; Bijlsma, R M; Imholz, A L T; Stathonikos, N; Vreuls, W; Sanders, J; Rosenberg, E H; Koop, E A; Varga, Z; van Deurzen, C H M; Mooyaart, A L; Córdoba, A; Groen, E; Bart, J; Willems, S M; Zolota, V; Wesseling, J; Sapino, A; Chmielik, E; Ryska, A; Broeks, A; Voogd, A C; van der Wall, E; Siesling, S; Salgado, R; Dackus, G M H E; Hauptmann, M; Kok, M; Linn, S C
(Elsevier, 2024-03)
Background: In the absence of prognostic biomarkers, most patients with early-stage triple-negative breast cancer (eTNBC) are treated with combination chemotherapy. The identification of biomarkers to select patients for ...